Top

Published in:

01-04-2005 | Original Article

High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse

Authors: Sevcan A. Bakkaloglu, Oguz Soylemezoglu, Necla Buyan, Tohru Funahashi, Atilla H. Elhan, Harun Peru, Kibriya Fidan, Sebahat Yılmaz, Enver Hasanoglu

Published in: Pediatric Nephrology | Issue 4/2005

Abstract

Adiponectin (ADPN), exclusively expressed and secreted from adipocytes, is a recently discovered protein hormone with anti-atherogenic and anti-inflammatory properties in contrast to other well-known adipocytokines. It has independent negative associations with obesity and hyperinsulinemia/insulin resistance. Apart from chronic renal failure, nephrotic syndrome was suggested as the only renal disease condition associated with raised plasma ADPN levels in adults. We aimed to evaluate the effect of nephrotic state on serum adiponectin (ADPN) levels in pediatric patients with steroid-responsive nephrotic syndrome (SRNS) by comparing the levels in relapse and remission as well as in control subjects and documenting possible relationships between ADPN and proteinuria as well as serum protein/lipid parameters. 34 patients with SRNS and 22 healthy age, sex and BMI-matched control subjects were enrolled into the study. 15 of the 34 SRNS patients had active diseases, and these were known as the SRNS-relapse group (ten relapsed and five newly-diagnosed patients), while the remaining 19 were in complete remission (the SRNS-remission group). Serum ADPN levels, blood chemistry (protein/albumin, triglyceride (TG), cholesterol (Cho) and lipoprotein levels) and 24-hour proteinuria were studied. ADPN levels were determined by ELISA. As expectedly, there were significant alterations in serum protein-lipid parameters and 24-hour proteinuria levels in SRNS patients consistent with their disease activity. SRNS-relapse patients had substantially higher ADPN levels (36.77±15.06 (5.61–59.41, median 39.84) μg/ml), compared to those in SRNS-remission and control groups (14.17±6.02 (3.28–29.40, median 12.80) μg/ml and 11.84±7.53 (2.81–31.46, median 10.85) μg/ml, respectively, p=0.001). There were strong positive correlations between serum ADPN levels and Cho (r=0.637, p=0.000), TG (r=0.516, p=0.002), low density lipoprotein (r=0.614, p=0.000) levels and 24-hour proteinuria (r=0.828, p=0.000) levels, whereas protein (r=−0.695, p=0.000) and albumin (r=0.732, p=0.000) levels were inversely correlated with ADPN levels. Regression analysis showed a significant correlation between ADPN and proteinuria (p=0.000). In conclusion, remarkably increased serum ADPN levels were detected in SRNS-relapse compared to those in SRNS-remission. This phenomenon might be the reflection of a compensatory response to nephrotic state characterized by massive proteinuria, hypoalbuminemia and hyperlipidemia.

Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Bioph Res Co 221:286–289CrossRef

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476

Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through cAMP-dependent pathway. Circulation 102:1296–1301

Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMed

Trayhurn B, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. P Nutr Soc 60:329–339

Auwerx J, Bouiloon R, Collen D, Geboers J (1988) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68–72

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Bioph Res Co 257:79–83CrossRef

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscl Throm Vas 20:1595–1599

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocr Metab 86:1930–1935CrossRef

10.

Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA (2002) Plasma adiponectin concentrations in children: Relationships with obesity and insulinemia. J Clin Endocr Metab 87:4652–4656CrossRef

11.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–41

12.

Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2003) Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 84:S98–102CrossRef

13.

Ozata M, Oktenli C, Gulec M, Ozgurtas T, Bulucu F, Caglar K, Bingol N, Vural A, Ozdemir IC (2002) Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocr Metab 87:853–8CrossRef

14.

Buyan N, Ozkaya O, Bideci A, Soylemezoglu O, Cinaz P, Gonen S, Kalman S, Bakkaloglu S, Hasanoglu E (2003) Leptin, soluble leptin receptor, and transforming growth factor-beta1 levels in minimal change nephrotic syndrome. Pediatr Nephrol 18:1009–1014

15.

Schroth M, Kratzsch J, Groschl M, Rauh M, Rascher W, Dotsch J (2003) Increased soluble leptin receptor in children with nephrotic syndrome. J Clin Endocr Metab 88:5497–501CrossRef

16.

International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159–165PubMed

17.

International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564PubMed

18.

Clarck AG, Barratt TM (1999) Steroid responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology, 4th edn. Lippincott Williams & Wilkins, Baltimore, MD, pp 731–747

19.

Hoyer PF, Honda S, Barthels M, Krohin HP, Brodehl J (1986) Thromboembolic complications in children with nephrotic syndrome. Acta Pediatr Scand 75:804–810

20.

Zimmerman RL, Novek S, Chen JT, Roggli V (1994) Pulmonary thrombosis in a 10-year-old child with minimal change disease and nephrotic syndrome. A clinical, radiologic, and pathologic correlation with literature review. Am J Clin Pathol 101:230–236PubMed

21.

Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J (1984) Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 104:61–64

22.

Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, Kakei M, Fujishima H, Ito S (2004) Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Bioph Res Co 316:165–169CrossRef

23.

Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed

Title: High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse
Authors: Sevcan A. Bakkaloglu
Oguz Soylemezoglu
Necla Buyan
Tohru Funahashi
Atilla H. Elhan
Harun Peru
Kibriya Fidan
Sebahat Yılmaz
Enver Hasanoglu
Publication date: 01-04-2005
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 4/2005
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-004-1770-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2005

The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1

Glycosaminoglycan excretion in children with nephrotic syndrome

Jeremy Levy, Julie Morgan, Edwina Brown (eds): Oxford handbook of dialysis, 2nd edn

Catastrophic antiphospholipid syndrome in a 14-year-old child

A novel epithelial sodium channel β-subunit mutation associated with hypertensive Liddle syndrome

Outcome of patients with antenatally detected pelviureteric junction obstruction